<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Penicillin G benzathine (long-acting intramuscular): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Penicillin G benzathine (long-acting intramuscular): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Penicillin G benzathine (long-acting intramuscular): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11245" href="/d/html/11245.html" rel="external">see "Penicillin G benzathine (long-acting intramuscular): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12686" href="/d/html/12686.html" rel="external">see "Penicillin G benzathine (long-acting intramuscular): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F7272304"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate administration:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Not for IV use. Do not inject IV or admix with other IV solutions. There have been reports of inadvertent IV administration of penicillin G benzathine that has been associated with cardiorespiratory arrest and death. Prior to administration of this drug, carefully read the Warnings, Adverse Reactions, Dosage, and Administration sections of the labeling.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F207570"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bicillin L-A</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867880"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Bicillin L-A</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F207608"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Penicillin</li></ul></div>
<div class="block doa drugH1Div" id="F207574"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range: IM:</b> 1.2 to 2.4 million units as a single dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cellulitis, long-term suppression of recurrent infection (off-label use):</i>
<b>Note:</b> For patients with recurrent presumptive beta-hemolytic streptococcal cellulitis at the same anatomical site despite addressing predisposing factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stevens.1','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stevens.1','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM: </b>1.2 to 2.4 million units as a single dose every 2 to 4 weeks after completion of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26475200','lexi-content-ref-Stevens.1','lexi-content-ref-16898904','lexi-content-ref-9314462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26475200','lexi-content-ref-Stevens.1','lexi-content-ref-16898904','lexi-content-ref-9314462'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f2098d-7a15-436e-bc6b-422791b57466">
<i>Streptococcus</i>, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Streptococcus</i>, group A:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pharyngitis:</i>
<b>IM:</b> 1.2 million units as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689','lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689','lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary prophylaxis in patients with rheumatic fever (prevention of recurrent attacks):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>In patients at elevated risk of death from cardiovascular compromise with IM penicillin (eg, severe valvular disease, ventricular ejection fraction &lt;50%, NYHA class III/IV symptoms), oral penicillin V potassium may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35049336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35049336'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 1.2 million units once every 21 to 28 days. Duration depends on risk factors, age, and presence of valvular heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic carriage (off-label use):</i>
<b>Note:</b> Most individuals with chronic carriage do not require antimicrobial treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 1.2 million units as a single dose in combination with 4 days of oral rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27c158d1-f522-4d2c-a14b-8b661d97b007">Syphilis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Syphilis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Early syphilis (primary, secondary, and early latent [&lt;1-year duration]):</i>
<b>IM:</b> 2.4 million units as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>). <b>Note:</b> Some experts recommend a second dose 1 week after the first dose in patients who are pregnant, given potential pharmacokinetic benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8355931','lexi-content-ref-27956203','lexi-content-ref-12353207']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8355931','lexi-content-ref-27956203','lexi-content-ref-12353207'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Late syphilis (late latent [ie, &gt;1-year duration] or tertiary syphilis with normal CSF examination):</i>
<b>IM:</b> 2.4 million units once weekly for 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neurosyphilis (including ocular and otosyphilis):</i>
<b>Note:</b> Not indicated for initial treatment; for late neurosyphilis (syphilis exposure &gt;1 year ago), may consider administration of penicillin G benzathine following initial IV penicillin G aqueous or IM penicillin G procaine therapy to provide a comparable total duration of therapy for late syphilis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM: </b>2.4 million units once weekly for 1 to 3 doses following 10 to 14 days of IV penicillin G aqueous or IM penicillin G procaine therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12c6a5ae-7e81-40ff-9bf8-fad0f7f2e490">Yaws, bejel, and pinta</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Yaws, bejel, and pinta:</b>
<b>IM:</b> 1.2 million units as a single dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990723"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988078"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F207575"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F207591"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12686" href="/d/html/12686.html" rel="external">see "Penicillin G benzathine (long-acting intramuscular): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f2098d-7a15-436e-bc6b-422791b57466">
<i>Streptococcus</i>, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Streptococcus</i>, group A:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pharyngitis/tonsillitis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689','lexi-content-ref-22965026','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689','lexi-content-ref-22965026','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">≤27 kg: IM: 600,000 units as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;27 kg: IM: 1,200,000 units (1.2 million units) as a single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rheumatic fever, secondary prevention: </i>Limited data available: <b>Note: </b>In patients at elevated risk of death from cardiovascular compromise with IM penicillin (eg, severe valvular disease, ventricular ejection fraction &lt;50%, NYHA class III/IV symptoms), oral penicillin V potassium may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35049336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35049336'])">Ref</a></span>). Duration depends on risk factors including number of previous attacks, risk of exposure to group A streptococcal infections, age, and presence of valvular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">≤27 kg: IM: 600,000 units every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;27 kg: IM: 1,200,000 units (1.2 million units) every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Every-4-week administration is recommended in the United States where rheumatic fever incidence is low; every 3 weeks should be used to maintain desirable serum drug concentrations in patients who have had a breakthrough episode despite every-4-week dosing and in areas where incidence of acute rheumatic fever remains high (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689','lexi-content-ref-7965439','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689','lexi-content-ref-7965439','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic carriage </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>)<i>:</i> Limited data available: <b>Note: </b>Most individuals with chronic carriage do not require antibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">≤27 kg: IM: 600,000 units as a single dose in combination with oral rifampin for 4 days.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;27 kg: IM: 1,200,000 units (1.2 million units) as a single dose in combination with oral rifampin for 4 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27c158d1-f522-4d2c-a14b-8b661d97b007">Syphilis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Syphilis:</b>
<b>Note:</b> Not recommended for the initial treatment of neurosyphilis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Congenital:</i> Limited data available:<b> Note: </b>Not recommended if disease is confirmed or highly probable, or clinical manifestations are present (including abnormal cerebrospinal fluid [CSF] studies); see guidelines for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IM: 50,000 units/kg/dose once weekly for up to 3 weeks; maximum dose: 2.4 million units/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary, secondary, or early latent (&lt;1 year duration): </i>Infants, Children, and Adolescents: IM: 50,000 units/kg once; maximum dose: 2.4 million units/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Re-treatment of primary, secondary, or early latent disease after failure of previous therapy:</i> Infants, Children, and Adolescents: IM: 50,000 units/kg/dose once weekly for 3 weeks; maximum dose: 2.4 million units/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>). <b>Note:</b> If CSF examination positive, treat as neurosyphilis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Late latent (&gt;1 year or unknown duration): </i>Infants, Children, and Adolescents: IM: 50,000 units/kg/dose once weekly for 3 weeks; maximum dose: 2.4 million units/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51152533"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51152534"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F207544"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse drug reactions are reported for penicillin G benzathine and/or other parenteral penicillin G formulations.</p>
<p style="text-indent:0em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cerebrovascular accident, hypersensitivity angiitis, hypotension, palpitations, pulmonary embolism, syncope, tachycardia, vasodepressor syncope, vasodilation, vasospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, diaphoresis, exfoliative dermatitis, gangrene of skin and/or other subcutaneous tissues, maculopapular rash, pallor, pruritus, skin mottling, skin or other tissue necrosis (Nicolau syndrome), skin ulceration at injection site, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Blood in stool, <i>Clostridioides difficile</i> associated diarrhea, <i>Clostridioides difficile</i> colitis, intestinal necrosis, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, impotence, priapism, proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, hemolytic anemia, leukopenia, lymphadenopathy, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms, Jarisch-Herxheimer reaction, serum sickness-like reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Abscess at injection site, atrophy at injection site, bleeding at injection site, bruising at injection site, cellulitis at injection site, hypersensitivity reaction at injection site, inflammation at injection site, injection site reaction (neurovascular damage), pain at injection site, residual mass at injection site, swelling at injection site, tissue necrosis at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, coma, confusion, dizziness, drowsiness, euphoria, fatigue, headache, localized warm feeling, nervousness, neurologic abnormality (neurogenic bladder), neuropathy, numbness of extremities, pain, seizure, transverse myelitis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthropathy, asthenia, exacerbation of arthritis, myoglobinuria, periosteal disease, rhabdomyolysis, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blindness, blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, renal disease, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, cyanosis, cyanotic extremities, dyspnea, hypoxia, laryngeal edema, pulmonary hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F207559"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to penicillin(s) or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F207541"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity (including cephalosporins), history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Serious anaphylactic reactions require immediate emergency treatment with epinephrine, oxygen, intravenous steroids and airway management (including intubation) as indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Severe cutaneous adverse reactions: Severe cutaneous adverse reactions (SCAR) (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis) have been reported; discontinue immediately if SCAR is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>Clostridioides</i>
<i>difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Syphilis/neurosyphilis use: CDC and AAP do not currently recommend the use of penicillin G benzathine for the initial treatment regimen for congenital syphilis or neurosyphilis due to reported treatment failures and lack of published clinical data on its efficacy (CDC [Workowski 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate administration: <b>[US Boxed Warning]: Not for IV use; cardiopulmonary arrest and death have occurred from inadvertent IV administration.</b> Administer by deep IM injection only. Quadriceps femoris fibrosis and atrophy have been reported after repeated IM injections of penicillin preparations into the anterolateral thigh. Injection into or near an artery or nerve could result in severe neurovascular damage or permanent neurological damage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use only for treatment of infections due to penicillin G sensitive gram positive organisms, few gram-negative organisms such as <i>Neisseria gonorrhoeae</i>, and some anaerobes and spirochetes. Use only for infections susceptible to the low and very prolonged serum concentrations of benzathine penicillin G.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878585"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Nicolau syndrome or other serious local damage may occur following IM injection; these effects may include intense/severe pain, edema, cutaneous lesion, pallor, mottling, or cyanosis of the extremity, significant necrosis and gangrene requiring fasciotomy or amputation of proximal portions of extremities, paralysis, permanent neurovascular and neurological damage, and in some cases lead to death (De Sousa 2008; Kim 2015; Quincer 2019; Zargarbashi 2023; manufacturer's labeling). Also known as embolia cutis medicamentosa, Nicolau syndrome may occur most often in patients &lt;12 years of age, particularly infants and small children (eg, &lt;3 years of age) (De Sousa 2008; Quincer 2019; manufacturer's labeling). While exact pathogenesis is uncertain, it is likely related to injection into or near the vasculature (Kim 2015; Quincer 2019; manufacturer's labeling). Pain is typically present immediately or within hours of injection and symptom progression follows over the course of hours to days (Alkan Bozkaya 2016; De Sousa 2008; Kim 2015; Ocak 2006; Zargarbashi 2023). Some suggest that the risk of Nicolau syndrome may be reduced through use of proper technique for IM injection of penicillin G benzathine, including appropriate needle length, selection of appropriate injection sites and associated maximum volumes within the muscle, use of the Z-track method for injection, and aspiration for 5 to 10 seconds prior to injection to ensure no blood return; injection should be stopped if the patient complains of severe, intense pain (De Sousa 2008; Goudjo 2022; Ocak 2006; Pullen 2005; Quincer 2019). The manufacturer recommends dorso- or ventrogluteal sites for deep IM injection. Several studies have suggested ventrogluteal injection may be appropriate in term neonates, infants, and young children; risk of severe injury may be lower compared to other locations (deltoid, anterolateral aspect of thigh) as the site is relatively distant to major nerves and blood vessels and thinnest layer of subcutaneous fat (Atay 2017; Cook 2006). Administration in the anterolateral thigh is not recommended because the area is more vascular; repeated IM injections may lead to quadriceps femoris fibrosis and atrophy. With repeat doses or doses that require multiple injections, vary the injection site (Ocak 2006; manufacturer's labeling).</p></div>
<div class="block foc drugH1Div" id="F207553"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bicillin L-A: 2,400,000 units/4 mL (4 mL) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Prefilled Syringe, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bicillin L-A: 600,000 units/mL (1 mL); 1,200,000 units/2 mL (2 mL) [contains methylparaben, propylparaben]</p></div>
<div class="block geq drugH1Div" id="F207537"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F207561"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Bicillin L-A Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600000 units/mL (per mL): $192.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1200000 units/2 mL (per mL): $166.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2400000 units/4 mL (per mL): $170.45</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867881"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Prefilled Syringe, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bicillin L-A: 1,200,000 units/2 mL (2 mL) [contains methylparaben, propylparaben]</p></div>
<div class="block adm drugH1Div" id="F207556"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IM: Warm to room temperature before administration to lessen the pain associated with injection. Administer by deep IM injection at a slow, steady rate in the dorsogluteal region (upper outer quadrant of the buttock) or the ventrogluteal region. Do not inject near an artery or a nerve; permanent neurological damage or gangrene may result. When doses are repeated, rotate the injection site. <b>Do not administer IV, intra-arterially, or SubQ.</b></p></div>
<div class="block admp drugH1Div" id="F52613557"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IM: For IM administration only; do <b>not</b> give IV, intra-arterially or SUBQ; <b>inadvertent IV administration has resulted in thrombosis, severe neurovascular damage, cardiac arrest, and death</b>. Do not inject near an artery or a nerve; Nicolau syndrome may occur and/or permanent damage may result.</p>
<p style="text-indent:0em;margin-top:2em;">Warm vial to room temperature before administration to lessen the pain associated with injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689','lexi-content-ref-AAP.1'])">Ref</a></span>). Application of manual pressure at the injection site immediately prior to administration has also been shown to reduce pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25487006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25487006'])">Ref</a></span>). Administer undiluted as deep IM injection at a slow, steady rate to avoid discomfort and needle blockage. The manufacturer recommends administration in the dorsogluteal region (upper outer quadrant of the buttock) or ventrogluteal site. Ventrogluteal site injection may be appropriate in term neonates, infants, and young children; risk of severe injury may be lower compared to other locations (deltoid, anterolateral aspect of thigh) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28884891','lexi-content-ref-16406175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28884891','lexi-content-ref-16406175'])">Ref</a></span>). With repeat doses or when multiple injections must be given for a single dose, rotate the injection site. Administration in the anterolateral thigh is not recommended; repeated IM injections may lead to quadriceps femoris fibrosis and atrophy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16874179','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16874179','lexi-content-ref-Manu.1'])">Ref</a></span>). Some suggest that the risk of Nicolau syndrome may be reduced through use of proper technique for IM injection including appropriate needle length, selection of appropriate injection sites and associated maximum volumes within the muscle, use of the Z-track method for injection, and aspiration for 5 to 10 seconds prior to injection to ensure no blood return; injection should be stopped if the patient complains of severe, intense pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18953160','lexi-content-ref-Goudjo.1','lexi-content-ref-16874179','lexi-content-ref-15988190','lexi-content-ref-31060806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18953160','lexi-content-ref-Goudjo.1','lexi-content-ref-16874179','lexi-content-ref-15988190','lexi-content-ref-31060806'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F207554"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute glomerulonephritis:</b> Secondary prophylaxis in patients with a history of acute glomerulonephritis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A:</b> Secondary prophylaxis for rheumatic fever (prevention of secondary attacks).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A:</b> Treatment of pharyngitis caused by group A <i>Streptococcus</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Syphilis and other venereal diseases:</b> Treatment of syphilis, yaws, bejel, and pinta.</p></div>
<div class="block off-label drugH1Div" id="F52114563"><span class="drugH1">Use: Off-Label: Adult</span><p>Cellulitis, long-term suppression of recurrent infection; Streptococcal (group A) chronic carriage</p></div>
<div class="block mst drugH1Div" id="F207616"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Penicillin may be confused with penicillAMINE</p>
<p style="text-indent:-2em;margin-left:4em;">Penicillin G benzathine may be confused with penicillin G (parenteral/aqueous), penicillin G procaine, penicillin V potassium</p>
<p style="text-indent:-2em;margin-left:4em;">Bicillin may be confused with Wycillin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Penicillin G benzathine may only be administered by deep intramuscular injection; intravenous administration of penicillin G benzathine has been associated with cardiopulmonary arrest and death.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bicillin C-R (penicillin G benzathine and penicillin G procaine) may be confused with Bicillin L-A (penicillin G benzathine). Penicillin G benzathine is the only product currently approved for the treatment of syphilis. Administration of penicillin G benzathine and penicillin G procaine combination instead of Bicillin L-A may result in inadequate treatment response.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299839"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F207546"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F5720604"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Penicillin G benzathine crosses the placenta (Nathan 1993; Weeks 1997).</p>
<p style="text-indent:0em;margin-top:2em;">Penicillin is widely used in pregnant women. Based on available data, penicillin is generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Galvao 2013; Heinonen 1977; Lamont 2014; Muanda 2017a; Muanda 2017b).</p>
<p style="text-indent:0em;margin-top:2em;">Penicillin G is the drug of choice for treatment of syphilis during pregnancy (CDC [Workowski 2021]). Untreated maternal syphilis can cause congenital syphilis which is associated with bone deformities, neurologic impairment, stillbirth, or neonatal death (USPSTF [Curry 2018]). Symptoms of congenital syphilis may include hepatosplenomegaly, jaundice, nonimmune hydrops, pseudoparalysis of an extremity, rhinitis, or skin rash. The Centers for Disease Control and Prevention (CDC) Sexually Transmitted Diseases Treatment Guidelines provide recommendations for the treatment of syphilis in pregnant patients. The penicillin regimen (dose, duration, and preparation) for the treatment of pregnant patients is the same as for a nonpregnant patient and depends on the stage of syphilis. However, parenteral penicillin G is the only agent with documented efficacy in pregnancy. Patients who are allergic to penicillin should be desensitized and treated with penicillin. Pregnant patients being treated for latent syphilis must repeat the full course of therapy if any doses are missed. A Jarisch-Herxheimer reaction may occur in any patient within the first 24 hours of therapy, including pregnant patients. This reaction may induce early labor, fetal distress, or stillbirth (rare); however, it is not a reason to prevent or delay maternal therapy (CDC [Workowski 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Use of penicillin G benzathine should be continued for the secondary prophylaxis of rheumatic fever/heart disease during pregnancy when indicated (Russell 2018).</p></div>
<div class="block brc drugH1Div" id="F5694831"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Soluble penicillin G is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Concentrations of penicillin class antibiotics in breast milk are limited (Nau 1987). In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">Although the manufacturer recommends that caution be exercised when administering penicillin G benzathine to breastfeeding patients, penicillin G benzathine is considered compatible with breastfeeding when used in usual recommended doses (WHO 2002).</p></div>
<div class="block mop drugH1Div" id="F207551"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for signs and symptoms of anaphylaxis during first dose</p></div>
<div class="block pha drugH1Div" id="F207540"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall death and resultant bactericidal activity against susceptible bacteria</p></div>
<div class="block phk drugH1Div" id="F207558"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: 1 to 4 weeks (dose dependent); larger doses result in more sustained levels</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: IM: Slow </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Minimal concentrations attained in CSF with inflamed or uninflamed meninges; highest levels in the kidney; lesser amounts in liver, skin, intestines</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein Binding: ~60% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Within 12 to 24 hours; serum levels are usually detectable for 1 to 4 weeks depending on the dose; larger doses result in more sustained levels rather than higher levels</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Excreted by renal tubular excretion; penicillin G is detected in urine for up to 12 weeks after a single IM injection; renal clearance is delayed in neonates, young infants, and patients with impaired renal function</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F207562"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Depo pen | Extencilline | Penadur</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Retarpen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bicillin L A</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Penadur</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Benzetacil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Penicilina g benzatinica</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Benzacillin | Depo pen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Extencilline</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Retarpen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Benzil B Bha | Benzilpenicillina benzatinica biopharma | Sigmacillina</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Stelues</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Penidural</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bicillin l-a</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bicillin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Benza L a</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bicillin la | Permapen</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Benzilpenicilina benzatinica</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Depo-Pen | Retarpen</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Retarpen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Benzapen | Penadur</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bicillin l-a</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Benzetacil L.A</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Penilente</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al' The National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27164354">
<a name="27164354"></a>Alkan Bozkaya T, Demirel G, Ormeci T, et al. Anticoagulant and vasodilator therapy for Nicolau syndrome following intramuscular benzathine penicillin injection in a 4 year old boy. Tratamiento anticoagulante y vasodilatador para el síndrome de Nicolau tras la administración de una inyección de bencilpenicilina benzatínica intramuscular a un niño de cuatro años de edad. <i>Arch Argent Pediatr</i>. 2016;114(3):e184-e186. doi:10.5546/aap.2016.eng.e184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/27164354/pubmed" id="27164354" target="_blank">27164354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28884891">
<a name="28884891"></a>Atay S, Yilmaz Kurt F, Akkaya G, Karatağ G, Ilhan Demir Ş, Çalidağ U. Investigation of suitability of ventrogluteal site for intramuscular injections in children aged 36 months and under. <i>J Spec Pediatr Nurs</i>. 2017;22(4):10.1111/jspn.12187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/28884891/pubmed" id="28884891" target="_blank">28884891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bicillin.1">
<a name="Bicillin.1"></a>Bicillin L-A (penicillin G benzathine) [prescribing information]. New York, NY: Pfizer Injectables; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bicillin.2">
<a name="Bicillin.2"></a>Bicillin L-A (penicillin G benzathine) [prescribing information]. New York, NY: Pfizer Injectables; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26475200">
<a name="26475200"></a>Chen HM, Li YL, Liu YM, et al. The experience of intramuscular benzathine penicillin for prophylaxis of recurrent cellulitis: a cohort study. <i>J Microbiol Immunol Infect</i>. 2017;50(5):613-618. doi:10.1016/j.jmii.2015.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/26475200/pubmed" id="26475200" target="_blank">26475200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7448577">
<a name="7448577"></a>Collart P, Poitevin M, Milovanovic A, et al, “Kinetic Study of Serum Penicillin Concentrations After Single Doses of Benzathine and Benethamine Penicillins in Young and Old People,” <i>Br J Vener Dis</i>, 1980, 56(6):355-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/7448577/pubmed" id="7448577" target="_blank">7448577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16406175">
<a name="16406175"></a>Cook IF, Murtagh J. Ventrogluteal area--a suitable site for intramuscular vaccination of infants and toddlers. <i>Vaccine</i>. 2006;24(13):2403-2408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/16406175/pubmed" id="16406175" target="_blank">16406175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30193283">
<a name="30193283"></a>Curry SJ, Krist AH, Owens DK, et al; US Preventive Services Task Force. Screening for syphilis infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. <i>JAMA</i>. 2018;320(9):911-917. doi:10.1001/jama.2018.11785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/30193283/pubmed" id="30193283" target="_blank">30193283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol</i>. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25487006">
<a name="25487006"></a>Derya EY, Ukke K, Taner Y, Izzet AY. Applying manual pressure before benzathine penicillin injection for rheumatic fever prophylaxis reduces pain in children. <i>Pain Manag Nurs</i>. 2015;16(3):328-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/25487006/pubmed" id="25487006" target="_blank">25487006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18953160">
<a name="18953160"></a>De Sousa R, Dang A, Rataboli PV. Nicolau syndrome following intramuscular benzathine penicillin. <i>J Postgrad Med</i>. 2008;54(4):332-334. doi:10.4103/0022-3859.43523<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/18953160/pubmed" id="18953160" target="_blank">18953160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23437138">
<a name="23437138"></a>Galvao TF, Silva MT, Serruya SJ, et al. Safety of benzathine penicillin for preventing congenital syphilis: a systematic review. <i>PLoS One</i>. 2013;8(2):e56463. doi:10.1371/journal.pone.0056463<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/23437138/pubmed" id="23437138" target="_blank">23437138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19246689">
<a name="19246689"></a>Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. <i>Circulation. </i>2009;119(11):1541-1551.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/19246689/pubmed" id="19246689" target="_blank">19246689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goudjo.1">
<a name="Goudjo.1"></a>Goudjo EUEM, Metchihoungbe CS, Mihluedo-Agbolan AK, et al. Nicolau syndrome: a series of three cases following drug's intramuscular injection in children. <i>J. Pediatr. Surg. Case Rep</i>. 2022;80:e102181. doi:10.1016/j.epsc.2022.102181</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al, “Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,” <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Heinonen.1">
<a name="Heinonen.1"></a>Heinonen OP, Slone D, Shapiro S. <i>Birth Defects and Drugs in Pregnancy</i>. Littleton, MA: Publishing Sciences Group, Inc; 1977.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2738782">
<a name="2738782"></a>Kaplan EL, Berrios X, Speth J, et al, “Pharmacokinetics of Benzathine Penicillin G: Serum Levels During the 28 Days After Intramuscular Injection of 1,200,000 Units,” <i>J Pediatr</i>, 1989, 115(1):146-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/2738782/pubmed" id="2738782" target="_blank">2738782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kim.1">
<a name="Kim.1"></a>Kim KK, Chae DS. Nicolau syndrome: a literature review. <i>World J Dermatol</i>. 2015;4(2):103-107. doi:10.5314/wjd.v4.i2.103</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7965439">
<a name="7965439"></a>Lue HC, Wu MH, Wang JK, Wu FF, Wu YN. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. <i>J Pediatr</i>. 1994;125(5 Pt 1):812-816.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/7965439/pubmed" id="7965439" target="_blank">7965439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017a;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017b;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8355931">
<a name="8355931"></a>Nathan L, Bawdon RE, Sidawi JE, Stettler RW, McIntire DM, Wendel GD Jr. Penicillin levels following the administration of benzathine penicillin G in pregnancy. <i>Obstet Gynecol</i>. 1993;82(3):338-342.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/8355931/pubmed" id="8355931" target="_blank">8355931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3301235">
<a name="3301235"></a>Nau H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. <i>Dev Pharmacol Ther</i>. 1987;10(3):174-198. doi:10.1159/000457744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/3301235/pubmed" id="3301235" target="_blank">3301235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16874179">
<a name="16874179"></a>Ocak S, Ekici B, Cam H, Taştan Y. Nicolau syndrome after intramuscular benzathine penicillin treatment. <i>Pediatr Infect Dis J</i>. 2006;25(8):749. doi:10.1097/01.inf.0000226941.85500.9b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/16874179/pubmed" id="16874179" target="_blank">16874179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8071762">
<a name="8071762"></a>Paryani SG, Vaughn AJ, Crosby M, et al, “Treatment of Asymptomatic Congenital Syphilis: Benzathine Versus Procaine Penicillin G Therapy,” <i>J Pediatr</i>, 1994, 125(3):471-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/ 8071762 /pubmed" id=" 8071762 " target="_blank"> 8071762 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15988190">
<a name="15988190"></a>Pullen RL Jr. Administering medication by the Z-track method. <i>Nursing</i>. 2005;35(7):24. doi:10.1097/00152193-200507000-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/15988190/pubmed" id="15988190" target="_blank">15988190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31060806">
<a name="31060806"></a>Quincer E, Jaggi P. Nicolau syndrome: a rare complication following intramuscular injection. <i>J Pediatr</i>. 2019;212:238-238.e2. doi:10.1016/j.jpeds.2019.04.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/31060806/pubmed" id="31060806" target="_blank">31060806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27956203">
<a name="27956203"></a>Rac MW, Revell PA, Eppes CS. Syphilis during pregnancy: a preventable threat to maternal-fetal health. <i>Am J Obstet Gynecol</i>. 2017;216(4):352-363. doi:10.1016/j.ajog.2016.11.1052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/27956203/pubmed" id="27956203" target="_blank">27956203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29608495">
<a name="29608495"></a>Russell EA, Walsh WF, Costello B, et al. Medical management of rheumatic heart disease: a systematic review of the evidence. <i>Cardiol Rev</i>. 2018;26(4):187-195. doi:10.1097/CRD.0000000000000185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/29608495/pubmed" id="29608495" target="_blank">29608495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35049336">
<a name="35049336"></a>Sanyahumbi A, Ali S, Benjamin IJ, et al. Penicillin reactions in patients with severe rheumatic heart disease: a presidential advisory from the American Heart Association. <i>J Am Heart Assoc</i>. 2022;11(5):e024517. doi:10.1161/JAHA.121.024517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/35049336/pubmed" id="35049336" target="_blank">35049336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22965026">
<a name="22965026"></a>Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis. </i>2014;58(10):1496]. <i>Clin Infect Dis.</i> 2012;55(10):e86-e102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/22965026/pubmed" id="22965026" target="_blank">22965026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stevens.1">
<a name="Stevens.1"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16898904">
<a name="16898904"></a>Vignes S, Dupuy A. Recurrence of lymphoedema-associated cellulitis (erysipelas) under prophylactic antibiotherapy: a retrospective cohort study. <i>J Eur Acad Dermatol Venereol</i>. 2006;20(7):818-822. doi:10.1111/j.1468-3083.2006.01648.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/16898904/pubmed" id="16898904" target="_blank">16898904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9314462">
<a name="9314462"></a>Wang JH, Liu YC, Cheng DL, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. <i>Clin Infect Dis</i>. 1997;25(3):685-689. doi:10.1086/513752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/9314462/pubmed" id="9314462" target="_blank">9314462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9241301">
<a name="9241301"></a>Weeks JW, Myers SR, Lasher L, Goldsmith J, Watkins C, Gall SA. Persistence of penicillin G benzathine in pregnant group B streptococcus carriers. <i>Obstet Gynecol</i>. 1997;90(2):240-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/9241301/pubmed" id="9241301" target="_blank">9241301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12353207">
<a name="12353207"></a>Wendel GD Jr, Sheffield JS, Hollier LM, Hill JB, Ramsey PS, Sánchez PJ. Treatment of syphilis in pregnancy and prevention of congenital syphilis. <i>Clin Infect Dis</i>. 2002;35(suppl 2):S200-S209. doi:10.1086/342108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/12353207/pubmed" id="12353207" target="_blank">12353207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32806967">
<a name="32806967"></a>Zargarbashi R, Panjavi B, Keshavarz-Fathi M. Extensive deep tissue involvement in Nicolau syndrome and below-knee amputation: a case report and literature review. <i>Int J Low Extrem Wounds</i>. 2023;22(1):113-116. doi:10.1177/1534734620948768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-long-acting-intramuscular-drug-information/abstract-text/32806967/pubmed" id="32806967" target="_blank">32806967</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9551 Version 260.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
